Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO Sells $37,809.12 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James M. Frates sold 10,896 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the completion of the sale, the chief financial officer now owns 290,988 shares in the company, valued at $1,009,728.36. The trade was a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amylyx Pharmaceuticals Trading Down 2.3 %

Shares of AMLX traded down $0.08 during midday trading on Friday, hitting $3.43. The stock had a trading volume of 914,194 shares, compared to its average volume of 1,348,397. The business has a 50-day simple moving average of $3.55 and a two-hundred day simple moving average of $4.06. The firm has a market cap of $303.90 million, a P/E ratio of -0.90 and a beta of -0.53. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The company had revenue of ($0.67) million for the quarter. On average, analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Remove Ads

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AMLX. Blue Trust Inc. boosted its position in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after acquiring an additional 4,883 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth approximately $45,000. Alpine Global Management LLC purchased a new position in Amylyx Pharmaceuticals during the fourth quarter valued at approximately $45,000. RPO LLC acquired a new position in Amylyx Pharmaceuticals in the 4th quarter valued at approximately $46,000. Finally, EntryPoint Capital LLC acquired a new position in Amylyx Pharmaceuticals in the 4th quarter valued at approximately $53,000. Hedge funds and other institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.